Search results
Results From The WOW.Com Content Network
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
The company formulates over 12.5 crore doses of OPV and had aggregated revenues of ₹ 30.5 crore (equivalent to ₹ 98 crore or US$11 million in 2023) in fiscal 2006. [2] [3] BIBCOL is under the administrative control of the Department of Biotechnology, Ministry of Science and Technology.
Dr. Krishna Ella is an Indian scientist and entrepreneur.He is the founder and Executive Chairman of Bharat Biotech. [1] [2] Ella and his company were responsible for developing India's own COVID-19 vaccine, Covaxin, World's 1st clinically proven conjugated Typhoid Vaccine, TypbarTCV and ROTAVAC.
India's Bharat Biotech said on Tuesday its oral cholera vaccine cleared a late-stage trial and that it plans a global launch, aiming to make up to 200 million doses a year amid an expanding ...
Cambridge, MA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections, today announced a collaboration with Bharat Biotech for the co-development and commercialization of Alopexx’s proprietary broad-spectrum ...
The vaccine is produced with Bharat Biotech's in-house vero cell manufacturing platform [12] that has the capacity to deliver about 300 million doses. [13] The company is in the process of setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin.
Zhejiang Peptites Biotech also supplied at least 25.6 kg of semaglutide, valued about $2.8 million, to Russian drugmaker Geropharm in 2023 and 2024, according to Reuters calculations based on the ...
iNCOVACC (codenamed BBV154) [1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [2] [3] American company Precision Virologics [4] [5] and the Washington University School of Medicine in St Louis, Missouri, United States. [6] [7]